Physician profile
Rahim Shafa
NPI 1205920527
$46,623.84
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $7,785 · 2023: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22,008.13 | 2019-2023 | Rexulti |
| Alkermes, INC. | $16,595.57 | 2019-2020 | |
| Allergan, INC. | $4,604.28 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,000.00 | 2020 | |
| Sunovion Pharmaceuticals INC. | $504.07 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $436.67 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $203.59 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $178.92 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $177.23 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $176.69 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $166.00 | 2019-2020 | |
| Lundbeck LLC | $140.07 | 2019 | |
| Abbvie INC. | $125.00 | 2023 | Vraylar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $88.15 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $46.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.30 | 2019 | |
| Assertio Therapeutics, INC. | $19.82 | 2019 | |
| Kaleo, INC. | $16.78 | 2019 | |
| Indivior INC. | $12.71 | 2019 | |
| Acadia Pharmaceuticals INC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahim Shafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.